Newsletters

[Lupus Foundation of America] The Lupus Foundation of America announced the recipients of the 2026 Gary S. Gilkeson Career Development Award. The two-year grant supports early career scientists at a pivotal time in their professions, providing funding for critical research studies and mentorship to foster the growth of the lupus research field.

[Immunity] Researchers investigated whether melanocyte-intrinsic transcriptional program(s) underlie immune tolerance to mutations resulting from UV radiation exposure.

[Experimental & Molecular Medicine] Emerging evidence highlights the intricate interplay between metabolic reprogramming and epigenetic modifications in macrophages, neutrophils, and other innate immune populations within the tumor microenvironment.

[Journal of Allergy and Clinical Immunology] Investigators explored the effects of the IL-2 mutein Fc.mut24 on allergen-induced type 2 airway inflammation. Fc.mut24 therapy prevented allergic airway inflammation when delivered before type 2 effector T cell priming but was insufficient to overcome established allergen-specific type 2 responses.

[Experimental & Molecular Medicine] Scientists propose a framework that overlays the cancer-immunity cycle with major metabolic checkpoints, including glucose and amino acid competition, acidosis and lipid overload, to clarify how distinct metabolic stresses create immune bottlenecks at different stages of the anti-tumour response.

[Journal of Experimental Medicine] Researchers found that infusions of orthogonal IL-2 failed to enhance Tregs expressing a corresponding orthoIL-2 receptor in a mouse model of autoimmune diabetes. Engineering Tregs with an orthoIL-2 tethered to its receptor achieved selective autocrine signaling.

[Cancer Research] Investigators used intratumoral delivery (IT) of diphtheria toxin in Foxp3DTR mice to deplete Tregs within tumor tissues while leaving peripheral Tregs intact. Mechanistically, IT Tregs suppressed antitumor T cell responses by blocking the acquisition and presentation of tumor antigen by conventional type II dendritic cells.

[Gut] Researchers characterised CSCs in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC) and investigated their contribution to MASLD-HCC tumourigenesis and therapy response.

[Signal Transduction and Targeted Therapy] The authors discusss current concepts of CSC origin and plasticity, the criteria used to define CSCs across different tumor types, and the marker systems as well as high-resolution technologies that are used to track CSC states.

[Cell Death DIscovery] Scientists found that the long noncoding RNA LINC02709 was upregulated in hepatocellular carcinoma and correlated with stemness properties, intrahepatic metastasis, and poor prognosis.

[Cell Reports] Researchers delineated the 3D chromatin landscapes of well- and poorly differentiated hepatocellular carcinoma cells and uncovered stemness-associated rewiring of A/B compartmentalization, topologically associating domain boundaries, and enhancer-promoter loops.

[Advanced Science] Investigators showed that mesenchymal (MES) glioma stem cells exhibit enhanced glycolytic activity and lactate production, driven in part by MES-associated transcriptional regulators that promote LDHA expression.